IBDEI0X9 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16168,1,5,0)
 ;;=5^Depression
 ;;^UTILITY(U,$J,358.3,16168,2)
 ;;=^35603
 ;;^UTILITY(U,$J,358.3,16169,0)
 ;;=250.01^^81^955^26
 ;;^UTILITY(U,$J,358.3,16169,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16169,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,16169,1,5,0)
 ;;=5^Diabetes, Type 1
 ;;^UTILITY(U,$J,358.3,16169,2)
 ;;=^331780
 ;;^UTILITY(U,$J,358.3,16170,0)
 ;;=250.00^^81^955^27
 ;;^UTILITY(U,$J,358.3,16170,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16170,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,16170,1,5,0)
 ;;=5^Diabetes, Type 2
 ;;^UTILITY(U,$J,358.3,16170,2)
 ;;=^331779
 ;;^UTILITY(U,$J,358.3,16171,0)
 ;;=305.90^^81^955^29
 ;;^UTILITY(U,$J,358.3,16171,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16171,1,4,0)
 ;;=4^305.90
 ;;^UTILITY(U,$J,358.3,16171,1,5,0)
 ;;=5^Drug Abuse-Unspec
 ;;^UTILITY(U,$J,358.3,16171,2)
 ;;=^268258
 ;;^UTILITY(U,$J,358.3,16172,0)
 ;;=305.93^^81^955^28
 ;;^UTILITY(U,$J,358.3,16172,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16172,1,4,0)
 ;;=4^305.93
 ;;^UTILITY(U,$J,358.3,16172,1,5,0)
 ;;=5^Drug Abuse-In Remission
 ;;^UTILITY(U,$J,358.3,16172,2)
 ;;=^268261
 ;;^UTILITY(U,$J,358.3,16173,0)
 ;;=796.2^^81^955^33
 ;;^UTILITY(U,$J,358.3,16173,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16173,1,4,0)
 ;;=4^796.2
 ;;^UTILITY(U,$J,358.3,16173,1,5,0)
 ;;=5^Elevated BP w/o HTN
 ;;^UTILITY(U,$J,358.3,16173,2)
 ;;=^273464
 ;;^UTILITY(U,$J,358.3,16174,0)
 ;;=607.84^^81^955^35
 ;;^UTILITY(U,$J,358.3,16174,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16174,1,4,0)
 ;;=4^607.84
 ;;^UTILITY(U,$J,358.3,16174,1,5,0)
 ;;=5^Erectile Dysfunction
 ;;^UTILITY(U,$J,358.3,16174,2)
 ;;=^270441
 ;;^UTILITY(U,$J,358.3,16175,0)
 ;;=530.81^^81^955^36
 ;;^UTILITY(U,$J,358.3,16175,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16175,1,4,0)
 ;;=4^530.81
 ;;^UTILITY(U,$J,358.3,16175,1,5,0)
 ;;=5^GERD
 ;;^UTILITY(U,$J,358.3,16175,2)
 ;;=^295749
 ;;^UTILITY(U,$J,358.3,16176,0)
 ;;=389.9^^81^955^39
 ;;^UTILITY(U,$J,358.3,16176,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16176,1,4,0)
 ;;=4^389.9
 ;;^UTILITY(U,$J,358.3,16176,1,5,0)
 ;;=5^Hearing Loss NOS
 ;;^UTILITY(U,$J,358.3,16176,2)
 ;;=^54552
 ;;^UTILITY(U,$J,358.3,16177,0)
 ;;=784.0^^81^955^38
 ;;^UTILITY(U,$J,358.3,16177,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16177,1,4,0)
 ;;=4^784.0
 ;;^UTILITY(U,$J,358.3,16177,1,5,0)
 ;;=5^Headaches
 ;;^UTILITY(U,$J,358.3,16177,2)
 ;;=^54133
 ;;^UTILITY(U,$J,358.3,16178,0)
 ;;=070.54^^81^955^40
 ;;^UTILITY(U,$J,358.3,16178,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16178,1,4,0)
 ;;=4^070.54
 ;;^UTILITY(U,$J,358.3,16178,1,5,0)
 ;;=5^Hepatitis C
 ;;^UTILITY(U,$J,358.3,16178,2)
 ;;=^303252
 ;;^UTILITY(U,$J,358.3,16179,0)
 ;;=272.4^^81^955^41
 ;;^UTILITY(U,$J,358.3,16179,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16179,1,4,0)
 ;;=4^272.4
 ;;^UTILITY(U,$J,358.3,16179,1,5,0)
 ;;=5^Hyperlipidemia
 ;;^UTILITY(U,$J,358.3,16179,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,16180,0)
 ;;=272.2^^81^955^42
 ;;^UTILITY(U,$J,358.3,16180,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16180,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,16180,1,5,0)
 ;;=5^Hyperlipidemia,Mixed
 ;;^UTILITY(U,$J,358.3,16180,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,16181,0)
 ;;=401.9^^81^955^43
 ;;^UTILITY(U,$J,358.3,16181,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16181,1,4,0)
 ;;=4^401.9
 ;;^UTILITY(U,$J,358.3,16181,1,5,0)
 ;;=5^Hypertension NOS
 ;;^UTILITY(U,$J,358.3,16181,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,16182,0)
 ;;=244.9^^81^955^44
 ;;^UTILITY(U,$J,358.3,16182,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16182,1,4,0)
 ;;=4^244.9
 ;;
 ;;$END ROU IBDEI0X9
